Full-Time

Senior Machine Learning Engineer

Confirmed live in the last 24 hours

Ceribell

Ceribell

201-500 employees

EEG devices for monitoring brain activity

Compensation Overview

$165k - $195k/yr

+ Bonus + Equity

Senior

Sunnyvale, CA, USA

Hybrid position with an in-office requirement of at least 3 times per week.

Category
Applied Machine Learning
Deep Learning
AI & Machine Learning
Required Skills
Scikit-learn
Python
Tensorflow
Git
Machine Learning
Requirements
  • Bachelor’s degree in Computer Science, Applied Mathematics, Electrical Engineering, or equivalent disciplines
  • Strong machine learning and deep learning fundamentals
  • Strong programming skills in Python
  • Prior experience with signal processing techniques (filtering, aliasing, wavelets)
  • 2+ Years of industry machine learning experience
  • Production experience using machine learning tools (Torch, TensorFlow, scikit-learn) and versioning (Git, CI/CD)
Responsibilities
  • Research and development of machine learning algorithms for neuro-diagnostics using EEG and other biosensors
  • Maintain and improve software pipelines for training and inference
  • Lead the transition of prototype machine-learning algorithms to robust, scalable real-time deployments
  • Participate in publications, clinical research and regulatory submissions
  • Collaborate with engineers on the team through code and design reviews
  • Communicate effectively with stakeholders within and outside the team
Desired Qualifications
  • Phd / Master’s degree in Computer Science, Applied Mathematics, Electrical Engineering, or equivalent disciplines and machine learning experience
  • Experience with machine learning management frameworks like MLflow, AirFlow, tensorboard, etc.

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on brain activity, which healthcare professionals can analyze to make informed treatment decisions, especially in urgent situations like Nonconvulsive Status Epilepticus (NCSE), where timely intervention is crucial. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they serve solely as tools for data collection. Ceribell differentiates itself by emphasizing the speed and efficiency of data gathering, which is vital in critical care scenarios. The company's goal is to enhance the ability of healthcare providers to monitor and respond to neurological conditions effectively.

Company Size

201-500

Company Stage

Series C

Total Funding

$171M

Headquarters

Mountain View, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • AI adoption in healthcare boosts demand for Ceribell's diagnostic tools.
  • Point-of-care testing trend increases adoption of portable diagnostic devices like Ceribell's.
  • Global EEG market growth supports Ceribell's expansion opportunities.

What critics are saying

  • Lock-up period expiration may cause stock volatility for Ceribell.
  • Recent earnings miss could affect investor confidence in Ceribell.
  • New executive appointments may lead to transitional challenges at Ceribell.

What makes Ceribell unique

  • Ceribell's EEG system offers instant results without needing a specialist interpreter.
  • The Brain Stethoscope function converts brainwaves to sound for easy seizure detection.
  • Ceribell's EEG system can be set up by any healthcare provider in 6 minutes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Holidays

Parental Leave

Annual Bonus Opportunity

Company Equity

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

2%
MarketBeat
May 11th, 2025
Barclays PLC Makes New Investment in CeriBell (NASDAQ:CBLL)

Barclays PLC makes new Investment in CeriBell (NASDAQ:CBLL).

Zolmax
Apr 8th, 2025
CeriBell's $180M Lock-Up Expires Tomorrow

CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.

BioSpace
Nov 20th, 2024
Ceribell Appoints Kristie Rodenbush As Chief People Officer And Brian Price As Senior Vice President Of Marketing

—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms

Fierce Biotech
Oct 15th, 2024
Ceribell CEO Jane Chao explains why now was the time for its upsized IPO

Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.

Renaissance Capital
Oct 7th, 2024
Seizure diagnostic company CeriBell sets terms for $101 million IPO

CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.